Hongyun Zhao
Sun Yat-sen University
PharmacokineticsCancerInternal medicinePathologyOncologyRandomized controlled trialAdverse effectHazard ratioLung cancerChemotherapyCarcinomaNasopharyngeal carcinomaEpidermal growth factor receptorGefitinibNon small cellCancer researchProportional hazards modelClinical trialMedicineGastroenterology
152Publications
26H-index
1,798Citations
Publications 151
Newest
#1Hongyun Zhao (SYSU: Sun Yat-sen University)H-Index: 26
#2Jibin Li (SYSU: Sun Yat-sen University)
view all 5 authors...
Source
#1Shen Zhao (SYSU: Sun Yat-sen University)H-Index: 7
#2Zhonghan Zhang (SYSU: Sun Yat-sen University)H-Index: 11
Last. Yunpeng Yang (SYSU: Sun Yat-sen University)H-Index: 26
view all 13 authors...
BACKGROUND With the identification of new targetable drivers and the recent emergence of novel targeted drugs, using comprehensive genomic profiling in lieu of the routine testing for classic drivers in the clinical care for advanced NSCLC has been increasingly advocated. However, the key assumption justifying this practice, that comprehensive genomic profiling could lead to effective anticancer therapies and improve patient outcomes, remains unproved. METHODS Comprehensive genomic profiling was...
Source
#1Fan Luo (SYSU: Sun Yat-sen University)H-Index: 5
#2Kangmei Zeng (SYSU: Sun Yat-sen University)H-Index: 2
Last. Yan Huang (SYSU: Sun Yat-sen University)H-Index: 36
view all 12 authors...
Background null Cancer patients often exhibit chemotherapy-associated changes in serum lipid profiles, however, their prognostic value before and after adjuvant chemotherapy on survival among non-small-cell lung cancer (NSCLC) patients is unknown. null Methods null NSCLC patients undergoing radical resection and subsequent adjuvant chemotherapy from 2013 to 2017 at Sun Yat-sen University Cancer Center were retrospectively reviewed. Fasted serum lipid levels were measured before and after chemoth...
Source
#1Hongyun Zhao (SYSU: Sun Yat-sen University)H-Index: 26
#2Zhonghan Zhang (SYSU: Sun Yat-sen University)H-Index: 11
Last. Li Zhang (SYSU: Sun Yat-sen University)H-Index: 64
view all 0 authors...
Source
#1Fan Luo (SYSU: Sun Yat-sen University)H-Index: 5
#2Jia-Xin Cao (SYSU: Sun Yat-sen University)
Last. Hongyun Zhao (SYSU: Sun Yat-sen University)H-Index: 26
view all 8 authors...
BACKGROUND Immunotherapy has shown promising efficacy in patients with nasopharyngeal carcinoma (NPC). Lymphocyte activating 3 gene (LAG-3) represents a significant immune target, however, its relationship with NPC remains unclear. This study aimed to evaluate LAG-3 expression in NPC and its association with CD3+ tumor-infiltrating lymphocytes (TILs), Granzyme B (GZMB), programmed death ligand 1 (PD-L1), and programmed death 1 (PD-1) expression. METHODS A total of 182 patients with NPC from Sun ...
Source
#1Zhonghan Zhang (SYSU: Sun Yat-sen University)H-Index: 11
#2Fan Luo (SYSU: Sun Yat-sen University)H-Index: 5
Last. Hongyun Zhao (SYSU: Sun Yat-sen University)H-Index: 26
view all 0 authors...
BACKGROUND The bispecific antibody (bsAbs) research around the world has undergone great changes. We analyzed the global trend of bsAbs research and compared the differences in clinical research of bsAbs between China and worldwide. METHODS BsAbs research clinical trials information was retrieved through the online open-resource clinical trial registration platform. Research information including organizations, identity numbers, locations, phases, participating centers, conditions, status, enrol...
Source
#1Fan Luo (SYSU: Sun Yat-sen University)H-Index: 5
#2Feiteng Lu (SYSU: Sun Yat-sen University)H-Index: 2
Last. Lin Zhang (SYSU: Sun Yat-sen University)H-Index: 69
view all 16 authors...
Advanced nasopharyngeal carcinoma (NPC) has a poor prognosis, with an unfavorable response to palliative chemotherapy. Unfortunately, there are few effective therapeutic regimens. Therefore, we require novel treatment strategies with enhanced efficacy. The present study aimed to investigate the antitumor efficacy of APG-1252-M1, a dual inhibitor of BCL-2/BCL-XL, as a single agent and combined with gemcitabine. We applied various apoptotic assays and used subcutaneous transplanted NPC model to as...
Source
#1Li ZhangH-Index: 64
#2Hongyun ZhaoH-Index: 26
Last. Zhuan Lin
view all 16 authors...
Source
#1Yang Wei (University of Electronic Science and Technology of China)
#2Benyuan Jiang (Guangdong General Hospital)
Last. Hongyun Zhao (SYSU: Sun Yat-sen University)H-Index: 26
view all 9 authors...
Abstract Introduction EGFR G724S has been described to mediate resistance to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs). In vitro experiments have provided compelling evidence that G724S retains sensitivity for afatinib. However, limited data have reported the clinical efficacy of afatinib in non-small cell lung cancer (NSCLC) patients harboring G724S mutation. Methods We identified 52 NSCLC patients with EGFR G724S from an in-house database, and comprehensively profiled ...
Source
#1Tingting Liu (SYSU: Sun Yat-sen University)H-Index: 1
#2Ting Zhou (SYSU: Sun Yat-sen University)H-Index: 19
Last. Yuanyuan Zhao (SYSU: Sun Yat-sen University)H-Index: 24
view all 9 authors...
Objectives:To investigate the clinical significance of dynamic alteration of serum lipids in limited stage small cell lung cancer (LS-SCLC) patients and the risk that different lipid profiles poses...
1 CitationsSource